- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03478306
Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm
July 30, 2021 updated by: Shakoor Ba-Ali, Glostrup University Hospital, Copenhagen
This study evaluates the effect of melatonin 4 mg on circadian rhythm and visual function of patients with diabetes mellitus.
Half of the patients will receive melatonin (arm-1) and the other half will receive placebo (arm-2), both groups in 3 weeks.
After a week of washout, the patients will cross over to the other treatment arm.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
RegionH
-
Glostrup, RegionH, Denmark, 2600
- Department of Ophthalmology, Rigshospitalet-Glostrup
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diabetic patients
- Age range 40-75 years
- Participant should be legally competent
Exclusion Criteria:
- Other known eye disease.
- Eye disease manifestation during ocular examination.
- Competing neurologic and systemic conditions affecting retina.
- Use of any drugs influencing pupillary light reflex and sleep pattern.
- Refractive error with need of > 6 diopter lenses.
- Pregnancy
- Alcohol consumption during the trial
- Lack of cooperation
- Allergy to melatonin and/or preservatives in melatonin and placebo
- Reduced hepatic function
- Fluvoxamin intake due to drug interaction
- Consumption of Alpha-1 and beta-1 adnergic antagoists.
- Alcohol consumption during treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1
Melatonin, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
|
Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
|
Placebo Comparator: Arm 2
Place, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
|
Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression of diabetic retinopathy, oscillary potential
Time Frame: 3 weeks
|
Progression of diabetic retinopati measured with electroretinography
|
3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-illumination pupillary light response
Time Frame: 3 weeks
|
Melanopsin-mediated pupillary response
|
3 weeks
|
Circadian photoentrainment
Time Frame: 3 weeks
|
Salivary melatonin level and sleep assessment
|
3 weeks
|
Retinal structure
Time Frame: 3 weeks
|
Retinal structure assessed by optical coherence tomography
|
3 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Shakoor Ba-Ali, Department of Ophthalmology, Rigshospitalet-Glostrup
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 27, 2018
Primary Completion (Actual)
June 12, 2021
Study Completion (Actual)
June 12, 2021
Study Registration Dates
First Submitted
March 20, 2018
First Submitted That Met QC Criteria
March 20, 2018
First Posted (Actual)
March 27, 2018
Study Record Updates
Last Update Posted (Actual)
August 2, 2021
Last Update Submitted That Met QC Criteria
July 30, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Dyssomnias
- Eye Diseases
- Neurologic Manifestations
- Endocrine System Diseases
- Diabetic Angiopathies
- Diabetes Complications
- Diabetes Mellitus
- Occupational Diseases
- Chronobiology Disorders
- Sleep Wake Disorders
- Retinal Diseases
- Diabetic Retinopathy
- Parasomnias
- Sleep Disorders, Circadian Rhythm
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Protective Agents
- Antioxidants
- Melatonin
Other Study ID Numbers
- DR2
- 2015-003955-23 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Retinopathy
-
Retina Institute of HawaiiUnknownDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Severe Nonproliferative Diabetic Retinopathy | Mild Nonproliferative Diabetic Retinopathy | Moderate Nonproliferative Diabetic RetinopathyUnited States
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoCompletedProliferative Diabetic Retinopathy | Severe Nonproliferative | Active Photocoagulated Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownNon Proliferative Diabetic Retinopathy. | Proliferative Diabetic Retinopathy.Mexico
-
Valo Health, Inc.RecruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
AEYE Health IncA. Stein Regulatory Affairs Consulting Ltd.RecruitingDiabetic Mellitus | Diabetic Retinopathy, DRUnited States
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
-
King Khaled Eye Specialist HospitalCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathySaudi Arabia
-
Retina Macula InstituteAllerganCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
Clinical Trials on Melatonin 4 mg Tablet
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Utrecht UniversityCompletedPharmacokinetics of MelatoninNetherlands
-
Pila PharmaCompletedDiabetes Mellitus, Type 2Denmark
-
University of Alabama at BirminghamEli Lilly and CompanyNot yet recruitingFrontal Fibrosing AlopeciaUnited States
-
Zydus Therapeutics Inc.RecruitingNon-alcoholic Fatty Liver Disease in Women With PCOSUnited States, Mexico
-
Chong Kun Dang PharmaceuticalCompletedHealthy Male VolunteerKorea, Republic of
-
Zydus Therapeutics Inc.CompletedPrimary Biliary CirrhosisUnited States
-
UCB Biopharma SRLWithdrawnEpilepsy | Healthy Participants
-
Stanford UniversityWithdrawn
-
PfizerCompletedNeurogenic Detrusor OveractivityBelgium